Sign In
Buy DSRLF
$78.45
+4.60 (+6.23%)
At Close: Jun 03, 2026
DiaSorin S.p.A. (DSRLF) Q1 2026 Earnings Call Transcript
06:21pm, Friday, 08'th May 2026
DiaSorin S.p.A. (DSRLF) Q1 2026 Earnings Call Transcript
Head to Head Contrast: Perrigo (NYSE:PRGO) and DiaSorin (OTCMKTS:DSRLF)
01:40am, Monday, 06'th Apr 2026
DiaSorin (OTCMKTS:DSRLF - Get Free Report) and Perrigo (NYSE: PRGO - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the st
DiaSorin S.p.A. (DSRLF) Q4 2025 Earnings Call Transcript
07:02pm, Friday, 20'th Mar 2026
DiaSorin S.p.A. (DSRLF) Q4 2025 Earnings Call Transcript
Head-To-Head Survey: Abbott Laboratories (NYSE:ABT) vs. DiaSorin (OTCMKTS:DSRLF)
01:46am, Monday, 26'th Jan 2026
DiaSorin (OTCMKTS:DSRLF - Get Free Report) and Abbott Laboratories (NYSE: ABT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based o
Head-To-Head Review: IM Cannabis (NASDAQ:IMCC) versus DiaSorin (OTCMKTS:DSRLF)
01:16am, Saturday, 13'th Dec 2025
DiaSorin (OTCMKTS:DSRLF - Get Free Report) and IM Cannabis (NASDAQ: IMCC - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on
Invesco International Small-Mid Company Fund Q3 2025 Portfolio Positioning
03:56am, Wednesday, 05'th Nov 2025
Invesco International Small-Mid Company Fund added six new positions and exited 11 positions during the quarter. We are benchmark independent, bottom-up investors, focusing on company fundamentals rat
DiaSorin: Anticipate A Double-Digit EBITDA Growth Rate
10:30am, Friday, 02'nd May 2025
DiaSorin's 2024 revenue grew by 3%, with an underlying increase of 7%, and net profit rose to 188.1M EUR, reflecting a 17% EPS increase. The company generated strong free cash flow of 191M EUR, enabli
DiaSorin S.p.A. (DSRLF) Q4 2024 Earnings Call Transcript
05:16pm, Friday, 14'th Mar 2025
DiaSorin S.p.A. (OTCPK:DSRLF) Q4 2024 Results Conference Call March 14, 2025 12:30 PM ET Company Participants Carlo Rosa - CEO Piergiorgio Pedron - CFO Conference Call Participants Kavya Deshpande - U
Italy's DiaSorin ex-Covid revenue in line with guidance
12:31pm, Friday, 14'th Mar 2025
Italian medical diagnostics group DiaSorin on Friday reported a 3% rise in 2024 revenue, citing dampened demand for its products with a milder Flu season compared to the previous year.
DiaSorin S.p.A. (DSRLF) Q2 2024 Earnings Call Transcript
06:41pm, Monday, 29'th Jul 2024
DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2024 Earnings Conference Call July 29, 2024 11:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen
DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript
07:25pm, Friday, 15'th Mar 2024
DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript
Diasorin 2023 revenue drops 14%, in line with guidance; shares fall
10:01am, Friday, 15'th Mar 2024
Italian medical diagnostic group Diasorin on Friday reported a double-digit drop in revenue for 2023, in line with its revenue guidance for the year, but shares dropped as much as 7.3%.
New Strong Sell Stocks for January 29th
04:26am, Monday, 29'th Jan 2024
T, DSRLF and HAFC have been added to the Zacks Rank #5 (Strong Sell) List on January 29, 2023.
DiaSorin S.p.A. (DSRLF) Q3 2023 Earnings Call Transcript
03:28pm, Friday, 03'rd Nov 2023
DiaSorin S.p.A. (OTCPK:DSRLF) Q3 2023 Earnings Conference Call November 3, 2023 11:30 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Confe
DiaSorin S.p.A. (DSRLF) Q2 2023 Earnings Call Transcript
10:01am, Saturday, 29'th Jul 2023
DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferenc
